On August 24, 2020 Tentarix reported that it was launched with a $50 Million Series A Financing and will leverage the ITS HuTARG core protein engineering platform to create multispecific binding molecules based on fully human antibody variable domains (Vds) (Press release, Tentarix Biotherapeutics, AUG 24, 2020, View Source [SID1234570452]). Tentarix’s mission is to develop first-in-class multispecific therapies. The Company is focused on modalities that have tissue specific function and is building a team that aims to transform biologics.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!